Postherpetic Neuralgia - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 98 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Postherpetic Neuralgia - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Postherpetic Neuralgia - Pipeline Review, H2 2016', provides an overview of the Postherpetic Neuralgia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Postherpetic Neuralgia
- The report reviews pipeline therapeutics for Postherpetic Neuralgia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Postherpetic Neuralgia therapeutics and enlists all their major and minor projects
- The report assesses Postherpetic Neuralgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Postherpetic Neuralgia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Postherpetic Neuralgia Overview 9
Therapeutics Development 10
Pipeline Products for Postherpetic Neuralgia - Overview 10
Postherpetic Neuralgia - Therapeutics under Development by Companies 11
Postherpetic Neuralgia - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Postherpetic Neuralgia - Products under Development by Companies 16
Postherpetic Neuralgia - Companies Involved in Therapeutics Development 17
Aestus Therapeutics, Inc. 17
ContraVir Pharmaceuticals, Inc. 18
Daewoong Pharmaceutical Co., Ltd. 19
Daiichi Sankyo Company, Limited 20
Immune Pharmaceuticals Inc. 21
Jiangsu Hengrui Medicine Co., Ltd. 22
KPI Therapeutics, Inc. 23
Lpath, Inc. 24
Merck & Co., Inc. 25
Patagonia Pharmaceuticals, LLC 26
Pfizer Inc. 27
Phosphagenics Limited 28
Relmada Therapeutics, Inc. 29
Scilex Pharmaceuticals, Inc. 30
Teva Pharmaceutical Industries Ltd. 31
Toray Industries, Inc. 32
Postherpetic Neuralgia - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Target 35
Assessment by Mechanism of Action 38
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
(amitriptyline + ketamine hydrochloride) - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
(clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
ATX-08001 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
bupivacaine hydrochloride - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
C-746 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
DWP-05195 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
funapide - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
FV-100 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
ketoprofen - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
lidocaine hydrochloride - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
lidocaine hydrochloride patch - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Lpathomab - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
mepivacaine hydrochloride - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
mirogabalin besylate - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
MK-8291 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
naltrexone hydrochloride - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
PATN-02 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
pregabalin CR - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
pregabalin SR - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
REL-1017 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
TRK-700 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
U-2902 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
zucapsaicin - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Postherpetic Neuralgia - Dormant Projects 84
Postherpetic Neuralgia - Discontinued Products 87
Postherpetic Neuralgia - Product Development Milestones 88
Featured News & Press Releases 88
Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles 88
May 12, 2016: SCILEX Pharmaceuticals Study Suggests Underutilization of Recommended First-Line Lidocaine Patches and Opioid Overuse for Treatment of Pain Associated with Post-Herpetic Neuralgias 88
Apr 22, 2016: SCILEX Pharmaceuticals Reports First-Line Treatments Including Lidocaine Patches for Post-Herpetic Neuralgia Are Significantly Underutilized 89
Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study 90
Dec 10, 2015: SCILEX Pharmaceuticals Announces Executive Hires 90
Sep 16, 2015: FDA Accepts SCILEX Pharmaceuticals' NDA Filing for ZTlido 91
Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial 91
Apr 02, 2015: Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia 91
Feb 20, 2015: ContraVir Pharmaceuticals Provides Clinical Update on FV-100 92
Feb 19, 2015: Xenon Pharmaceuticals Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia 92
Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 93
Jan 07, 2015: ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100 94
Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia 94
Aug 11, 2014: Scilex Pharmaceuticals Completes Trial Enrollment for Ztlido 95
Jul 14, 2014: SCILEX Pharmaceuticals Commences Dermal Safety Studies of Ztlido 95
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 97
Disclaimer 98

List of Tables

Number of Products under Development for Postherpetic Neuralgia, H2 2016 10
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Postherpetic Neuralgia - Pipeline by Aestus Therapeutics, Inc., H2 2016 17
Postherpetic Neuralgia - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016 18
Postherpetic Neuralgia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 19
Postherpetic Neuralgia - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 20
Postherpetic Neuralgia - Pipeline by Immune Pharmaceuticals Inc., H2 2016 21
Postherpetic Neuralgia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 22
Postherpetic Neuralgia - Pipeline by KPI Therapeutics, Inc., H2 2016 23
Postherpetic Neuralgia - Pipeline by Lpath, Inc., H2 2016 24
Postherpetic Neuralgia - Pipeline by Merck & Co., Inc., H2 2016 25
Postherpetic Neuralgia - Pipeline by Patagonia Pharmaceuticals, LLC, H2 2016 26
Postherpetic Neuralgia - Pipeline by Pfizer Inc., H2 2016 27
Postherpetic Neuralgia - Pipeline by Phosphagenics Limited, H2 2016 28
Postherpetic Neuralgia - Pipeline by Relmada Therapeutics, Inc., H2 2016 29
Postherpetic Neuralgia - Pipeline by Scilex Pharmaceuticals, Inc., H2 2016 30
Postherpetic Neuralgia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 31
Postherpetic Neuralgia - Pipeline by Toray Industries, Inc., H2 2016 32
Assessment by Monotherapy Products, H2 2016 33
Assessment by Combination Products, H2 2016 34
Number of Products by Stage and Target, H2 2016 36
Number of Products by Stage and Mechanism of Action, H2 2016 39
Number of Products by Stage and Route of Administration, H2 2016 42
Number of Products by Stage and Molecule Type, H2 2016 44
Postherpetic Neuralgia - Dormant Projects, H2 2016 84
Postherpetic Neuralgia - Dormant Projects (Contd..1), H2 2016 85
Postherpetic Neuralgia - Dormant Projects (Contd..2), H2 2016 86
Postherpetic Neuralgia - Discontinued Products, H2 2016 87